PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass
Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack…
Interviews
Will the tide turn for the wave of pharma layoffs?
Clinical research in the UK must build on industry collaboration, says NIHR director
How NVIDIA grew with the healthcare market instead of pushing into it
Drug development costs predicted to soar as BIOSECURE Act gains momentum
Boehringer Ingelheim plans sustainability work for the long term
Q&A: Cell and gene therapy value assessments need a rework to allow access
Q&A: BARDA wants to back tech that can combat multiple infections, says director
